Skip to content
DataLookout
Menu

BRAVONCT07903350

BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies

StatusRecruiting
PhasePhase 4
SponsorEpicentre
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Case fatality among laboratory-confirmed BVD cases hospitalized in Ebola health facilities
Timeframe: Up to 6 months after enrolment

Secondary (6)

Incidence of BVD-attributable death
Cumulative incidence of laboratory-confirmed BVD
Test-negative vaccine effectiveness
Severe disease among confirmed BVD cases
Serious adverse events (SAEs)
Show 1 moreShow less
Pregnancy and delivery outcomes among pregnant participants receiving ERVEBO®

Arms and interventions

Unvaccinated Frontline WorkersNo intervention

Frontline workers who do not receive ERVEBO® during the observation period and are followed for outcome assessment.

ERVEBO VaccinationExperimental

Frontline workers who receive ERVEBO® as part of the outbreak vaccination program

Biologicals: ERVEBO Vaccination

Sites

1 site in 1 country

  • Laboratoire Provincial de Santé et CTEBunia, Democratic Republic of the Congo